AUG 17 2026
Lantheus Holdings, Inc. — Tauklarify (florquinitau F 18) $LNTH
for Alzheimer's disease imaging
FDA approves Tauklarify (florquinitau F 18 injection), an F18-labeled tau PET imaging agent for use in Alzheimer's disease.
About
Tauklarify is a radioactive diagnostic tracer that binds to abnormal clumps of a protein called tau in the brain. These tau tangles are a key marker of the progressive brain changes seen in Alzheimer's disease. When injected into a patient, Tauklarify allows doctors to see where these tau deposits are located in the living brain, potentially aiding in diagnosis and care planning.
Drug Watch — recent news on Tauklarify
- Is FDA Approval Of TAUKLARIFY Alzheimer’s Tau PET Agent Altering The Investment Case For Lantheus (LNTH)? - simplywall.st
- FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify - Fierce Biotech
- FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease - Psychiatric Times
- FDA Approves Tauklarify to Identify Tau Pathology in Patients Being Evaluated for Alzheimer Disease - pharmacytimes.com
- Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease - Business Wire